Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310162547> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W4310162547 endingPage "12074" @default.
- W4310162547 startingPage "12073" @default.
- W4310162547 abstract "Background Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma in adults, and up to 40% of patients are refractory to front-line therapy or experience a relapse. In the relapsed/refractory (r/r) setting, novel treatment options are available, but many patients relapse following or are ineligible for such treatment options, due in part to their safety profiles. Thus, more effective, better tolerated therapeutic options are needed. Maveropepimut-S (MVP-S) leverages the DPX platform, a non-aqueous, lipid-based delivery system, to educate a specific, and persistent T cell-based immune response to HLA-restricted peptides of survivin, a cancer-associated protein commonly upregulated in advanced DLBCL. In a prior study in patients with r/r DLBCL (SPiReL), MVP-S with pembrolizumab and low dose, intermittent cyclophosphamide (CPA) led to durable complete and partial responses, and persistent, survivin-specific T cells, particularly in patients with PD-L1+ disease. Importantly, treatment was well-tolerated. Further exploration of the regimen in r/r DLBCL is warranted to confirm and extend these encouraging results. Methods The VITALIZE trial (NCT04920617) is a phase 2b, open-label, randomized trial of MVP-S and pembrolizumab, with or without intermittent low-dose CPA. Eligible patients have r/r persistent or progressive DLBCL following ≥ 2 lines of prior systemic therapy and are ineligible for, or have relapsed after, ASCT and/or CAR-T. Using a Simon's two-stage design, patients are randomized (1:1) to: Arm 1: MVP-S, pembrolizumab and CPA or Arm 2: MVP-S and pembrolizumab and will be treated for up to 2 years. The primary objective of the study is centrally assessed ORR, and secondary endpoints include PFS, DoR, DCR, OS and safety. Exploratory objectives include characterization of outcomes based on PD-L1 expression, and survivin-specific immunogenicity in baseline and on-treatment blood and tissue samples. This study will enroll up to 102 eligible patients at 65 global study sites. As of now, 21 sites are actively recruiting in US, Canada, Australia, New-Zealand, and France. Enrollment has begun. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
- W4310162547 created "2022-11-30" @default.
- W4310162547 creator A5001851740 @default.
- W4310162547 creator A5004066032 @default.
- W4310162547 creator A5045348716 @default.
- W4310162547 creator A5048340163 @default.
- W4310162547 creator A5049461398 @default.
- W4310162547 creator A5062280376 @default.
- W4310162547 creator A5064736890 @default.
- W4310162547 creator A5080834765 @default.
- W4310162547 date "2022-11-15" @default.
- W4310162547 modified "2023-09-28" @default.
- W4310162547 title "Vitalize Trial: A Phase 2b, Open-Label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of the Novel Immunotherapeutic, Maveropepimut-S, and Pembrolizumab with and without Intermittent Low-Dose Cyclophosphamide, in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma" @default.
- W4310162547 doi "https://doi.org/10.1182/blood-2022-159000" @default.
- W4310162547 hasPublicationYear "2022" @default.
- W4310162547 type Work @default.
- W4310162547 citedByCount "0" @default.
- W4310162547 crossrefType "journal-article" @default.
- W4310162547 hasAuthorship W4310162547A5001851740 @default.
- W4310162547 hasAuthorship W4310162547A5004066032 @default.
- W4310162547 hasAuthorship W4310162547A5045348716 @default.
- W4310162547 hasAuthorship W4310162547A5048340163 @default.
- W4310162547 hasAuthorship W4310162547A5049461398 @default.
- W4310162547 hasAuthorship W4310162547A5062280376 @default.
- W4310162547 hasAuthorship W4310162547A5064736890 @default.
- W4310162547 hasAuthorship W4310162547A5080834765 @default.
- W4310162547 hasBestOaLocation W43101625471 @default.
- W4310162547 hasConcept C121608353 @default.
- W4310162547 hasConcept C126322002 @default.
- W4310162547 hasConcept C141071460 @default.
- W4310162547 hasConcept C143998085 @default.
- W4310162547 hasConcept C2776694085 @default.
- W4310162547 hasConcept C2776755627 @default.
- W4310162547 hasConcept C2777701055 @default.
- W4310162547 hasConcept C2780057760 @default.
- W4310162547 hasConcept C31760486 @default.
- W4310162547 hasConcept C535046627 @default.
- W4310162547 hasConcept C71924100 @default.
- W4310162547 hasConceptScore W4310162547C121608353 @default.
- W4310162547 hasConceptScore W4310162547C126322002 @default.
- W4310162547 hasConceptScore W4310162547C141071460 @default.
- W4310162547 hasConceptScore W4310162547C143998085 @default.
- W4310162547 hasConceptScore W4310162547C2776694085 @default.
- W4310162547 hasConceptScore W4310162547C2776755627 @default.
- W4310162547 hasConceptScore W4310162547C2777701055 @default.
- W4310162547 hasConceptScore W4310162547C2780057760 @default.
- W4310162547 hasConceptScore W4310162547C31760486 @default.
- W4310162547 hasConceptScore W4310162547C535046627 @default.
- W4310162547 hasConceptScore W4310162547C71924100 @default.
- W4310162547 hasIssue "Supplement 1" @default.
- W4310162547 hasLocation W43101625471 @default.
- W4310162547 hasOpenAccess W4310162547 @default.
- W4310162547 hasPrimaryLocation W43101625471 @default.
- W4310162547 hasRelatedWork W2342781363 @default.
- W4310162547 hasRelatedWork W2610751918 @default.
- W4310162547 hasRelatedWork W2777867648 @default.
- W4310162547 hasRelatedWork W2786497694 @default.
- W4310162547 hasRelatedWork W2897815318 @default.
- W4310162547 hasRelatedWork W2904110710 @default.
- W4310162547 hasRelatedWork W2969782175 @default.
- W4310162547 hasRelatedWork W3153432702 @default.
- W4310162547 hasRelatedWork W3161613553 @default.
- W4310162547 hasRelatedWork W3215044659 @default.
- W4310162547 hasVolume "140" @default.
- W4310162547 isParatext "false" @default.
- W4310162547 isRetracted "false" @default.
- W4310162547 workType "article" @default.